Intest Res.  2025 Jan;23(1):1-2. 10.5217/ir.2024.00171.

In which patients with ulcerative colitis would filgotinib be effective?

• Park J

• KMID: 2564390
• DOI: http://doi.org/10.5217/ir.2024.00171

Reference

1. Honap S, Agorogianni A, Colwill MJ, et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2023; 15:59–69.

2. Shimizu H, Aonuma Y, Hibiya S, et al. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study. Intest Res. 2024; 22:369–377.

3. Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019; 7:e00537.

4. Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021; 397:2372–2384.

5. D’Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis. 2022; 16:835–844.

6. Ananthakrishnan AN. Precision medicine in inflammatory bowel diseases. Intest Res. 2024; 22:8–14.

7. Loftus EV, Vermeire S, Feagan BG, et al. Corticosteroid-sparing effects of filgotinib in moderately to severely active ulcerative colitis: data from the phase 2b/3 SELECTION study. J Crohns Colitis. 2023; 17:211–220.

8. Kobayashi T, Dignass A, Roblin X, et al. Filgotinib inductionstudy baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study. Intest Res. 2025; 23:65–75.